Genome-wide association study of short-acting β2-agonists. A novel genome-wide significant locus on chromosome 2 near ASB3.

ABSTRACT:

Rationale

β2-Agonists are the most common form of treatment of asthma, but there is significant variability in response to these medications. A significant proportion of this responsiveness may be heritable.

Objectives

To investigate whether a genome-wide association study (GWAS) could identify novel pharmacogenetic loci in asthma.

Methods

We performed a GWAS of acute bronchodilator response (BDR) to inhaled β2-agonists. A total of 444,088 single-nucleotide polymorphisms (SNPs) were examined in 724 individuals from the SNP Health Association Resource (SHARe) Asthma Resource Project (SHARP). The top 50 SNPs were carried forward to replication in a population of 444 individuals.

Measurements and main results

The combined P value for four SNPs reached statistical

SUBMITTER: Israel E 

PROVIDER: S-EPMC4384768 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature